Advancing Access is committed to helping patients afford their Gilead medication, including:

  • Atripla® (efavirenz/emtricitabine/tenofovir disoproxil fumarate); Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate); Descovy® (emtricitabine/tenofovir alafenamide ); Emtriva® (emtricitabine); Genvoya® (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide); Odefsey® (emtricitabine/rilpivirine/tenofovir alafenamide ); Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate); Truvada® (emtricitabine/tenofovir disoproxil fumarate); Tybost® (cobicistat); Vitekta® (elvitegravir); Viread® (tenofovir disoproxil fumarate)

Advancing Access provides assistance to appropriate patients who are uninsured, underinsured or who need financial assistance to pay for the medicine. The program offerings support services for patients and providers, including:

  • Access to counselors who can help patients and their providers with insurance-related questions, including providing information regarding coverage options.
  • The Advancing Access Copay Coupon Program, which provides co-pay assistance for eligible patients who need assistance paying for out-of-pocket medication costs.
  • The Advancing Access Patient Assistance Program and Truvada Medication Assistance Program, which will provide Gilead medications at no charge for eligible patients with no other insurance options.

Information about how to apply for any of these forms of assistance can be found at www.GileadAdvancingAccess.com or by calling 1-800-226-2056 between 9:00 a.m. and 8:00 p.m. (Eastern).